Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

This phase I/II is studying the side effect and best dose of Z-208 for patients with advanced hepatocellular carcinoma

Phase 1/Phase 2

Zeria Pharmaceutical